Uganda Receives 3,000 Doses for Investigational Ebola Vaccine Trial

Uganda has secured a significant number of investigational doses for a crucial clinical trial focusing on the Bundibugyo Ebola virus. The country has received approximately 3,000 doses of the ChAdOx BDBV vaccine candidate, which is currently undergoing Phase I clinical evaluation.

The trial, launched in Masaka City, is a collaborative effort involving the Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) and the London School of Hygiene and Tropical Medicine (LSHTM). Researchers are working alongside international partners, including the University of Oxford’s Oxford Vaccine Group and Pandemic Science Institute.

“The Bundibugyo virus disease is a form of Ebola with no approved vaccine or specific treatment,” stated Professor Eugene Rugazira, the principal investigator for the Uganda study. He emphasized that evaluating this vaccine candidate in Uganda is vital for generating evidence on its safety and immunogenicity, which could protect at-risk communities during future outbreaks.

This initiative is part of a broader program funded by the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of this vaccine candidate. A parallel study is also underway in the United Kingdom to evaluate the same vaccine. The ChAdOx BDBV vaccine candidate was developed by scientists at the University of Oxford, with large-scale manufacturing and stockpiling of doses by the Serum Institute of India (SII).

Experts believe that if successful, this vaccine could play a critical role in reducing transmission and mortality rates associated with Bundibugyo Ebola virus outbreaks, particularly given the current fast-growing epidemic in the Democratic Republic of Congo. The successful trial in Uganda underscores the nation’s growing capacity as a center for vaccine research in Africa.